A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Three recently-discovered molecular subtypes may help in crafting a more personalized treatment plan for men with prostate cancer. There are three distinct molecular subtypes of primary prostate ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form.

In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it ANN ARBOR, Michigan — When researchers at the University of ...

Real world data of precision medicine in the management of metastatic prostate cancer: A retrospective cohort study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1 ANN ARBOR, Michigan — Researchers at the University of ...